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Context: That serotonin plays a role in the regulation of feeding behavior and energy
metabolism has been known for a long time. Serotonin transporters (SERT) play a
crucial role in serotonin signaling by regulating its availability in the synaptic cleft. The
neuroanatomy underlying serotonergic signaling in humans is largely unknown, and until
now, SERT immunoreactivity in relation to body weight has not been investigated.
Objective: To clarify the distribution of SERT immunoreactivity throughout the human
hypothalamus and to compare SERT immunoreactivity in the infundibular nucleus (IFN),
the human equivalent of the arcuate nucleus, in lean and overweight subjects.
Design: First, we investigated the distribution of serotonin transporters (SERT) over the
rostro-caudal axis of six post-mortem hypothalami by means of immunohistochemistry.
Second, we estimated SERT immunoreactivity in the IFN of lean and overweight
subjects. Lastly, double-labeling of SERT with Neuropeptide Y (NPY) and melanocortin cell
populations was performed to further identify cells showing basket-like SERT staining.
Results: SERT-immunoreactivity was ubiquitously expressed in fibers throughout the
hypothalamus and was the strongest in the IFN. Immunoreactivity in the IFN was lower
in overweight subjects (p = 0.036). Basket-like staining in the IFN was highly suggestive
of synaptic innervation. A very small minority of cells showed SERT double labeling with
NPY, agouti-related protein and α–melanocyte stimulating hormone.
Conclusions: SERT is ubiquitously expressed in the human hypothalamus. Strong SERT
immunoreactivity, was observed in the IFN a region important for appetite regulation,
in combination with lower SERT immunoreactivity in the IFN of overweight and obese
subjects, may point toward a role for hypothalamic SERT in human obesity.
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INTRODUCTION
The brain serotonin (5-HT) system is known to be involved in
the regulation of food intake and body weight. Several animal
experimental studiesmanipulating endogenous serotonin synthe-
sis, availability and metabolism, have made it clear that there is
a negative relationship between the level of brain serotonin and
food intake, in which increasing serotonin (by inhibiting reuptake
or activating serotonin receptors post-synaptically) inhibits food
intake (Lam et al., 2010). In addition, over the last few years evi-
dence has accumulated on the central serotonin system’s involve-
ment in peripheral glucose metabolism (Lam and Heisler, 2007).
A more recent study reports that serotonin transporter (SERT)
knockout mice are obese and present pre-diabetic symptoms such
as glucose intolerance and insulin resistance (Chen et al., 2012).
A key brain area involved in the regulation of feeding behav-
ior and in peripheral glucose metabolism is the hypothalamus.
There are a number of anatomically distinct nuclei within the
hypothalamus that are involved in these functions and that
are closely interrelated (Saper et al., 2002). A central role in
this is played by the arcuate nucleus (ARC), or infundibular
nucleus (IFN) as it is referred to in humans (Swaab, 2003).
Several neuropeptides related to both feeding behavior and glu-
cose metabolism have been localized in the ARC/IFN. Like has
been shown for rodents, Neuropeptide Y (NPY), agouti-related
protein (AGRP) and α-melanocyte stimulating hormone (αMSH)
are localized in the human IFN (Goldstone et al., 2002; Alkemade
et al., 2012; Saderi et al., 2012). When these neuropeptides are
injected into the rodent brain, NPY and AGRP increase feeding,
reduce insulin sensitivity, and increase glucose production. On
the other hand, αMSH decreases food intake and increases insulin
action, thus reducing glucose production and enhancing glucose
uptake (for review: Arble and Sandoval, 2013). More recently we
investigated the expression of these neuropeptides in the human
IFN in relation to body mass index (BMI), and type 2 diabetes
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(Alkemade et al., 2012). We found that AGRP expression showed
a U-shaped correlation with BMI, and that NPY expression was
lower in overweight and obese subjects, whereas αMSH revealed
no relation to BMI.
Although it is clear that serotonin has an effect on feeding
behavior and glucose metabolism in the rodent hypothalamus,
data on human hypothalamus are scarce. What has been shown
in humans is that polymorphisms related to serotonergic signal-
ing are associated with BMI (Heisler and Tecott, 1999; Sookoian
et al., 2008), however this does not provide evidence for hypotha-
lamic serotonin as serotonin signals throughout the body and
also widely throughout the brain. We did recently show that
hypercaloric high fat high sugar snacking reduces diencephalic
SERT (Koopman et al., 2013). Although diencephalon contains
hypothalamus, it remains to be determined whether SERT con-
taining cells/fibers can be identified in the human IFN and other
hypothalamic nuclei. If identified, the question arises which indi-
vidual nuclei contain the densest SERT staining and how SERT
staining in the IFN relates to neuropeptides known to be involved
in energy metabolism.
In this paper we determined the distribution of SERT
immunoreactivity in the human hypothalamus using a post-
mortem approach. In addition, we compared SERT staining
in the IFN of subjects with a BMI < 25 to that of subjects
with a BMI ≥ 25 kg/m2. Finally, we describe immunofluorescent
double-labeling of SERT with the IFN neuropeptides NPY, AgRP,
and αMSH to identify cell types showing basket-like staining of
SERT-immunoreactive fibers, suggestive of synaptic innervation.
MATERIALS AND METHODS
SUBJECTS
For Experiment 1 we investigated the distribution of SERT using
systematic sampling over the entire rostro-caudal axis of the
hypothalamus of 6 subjects (3 male) without neurological or
psychiatric disease ranging in age between 67 and 86 years.
Clinicopathological and relevant medication data are presented
in Table 1.
For Experiment 2 in which we related SERT staining in the
IFN to BMI, we studied post-mortem hypothalamic tissue of 11
overweight and obese (6 male, median BMI 30.5 (range: 25.0–
39.5) kg/m2; median age 76 (range: 65–100) years) with 12 non-
obese (5 male, median BMI 20.1 (range15.2–24.2) kg/m2; median
age 64 (range: 50–92) years) subjects. Clinicopathological and
relevant medication data have been published earlier (Alkemade
et al., 2012), and are presented in the Table 2.
In experiment 3 we aimed to identify the immunocytochemi-
cal nature of the cells showing basket-like SERT immunoreactiv-
ity, using brain material of the subjects described in Experiment
1. All brain material was obtained from The Netherlands Brain
Bank at The Netherlands Institute for Neuroscience (director Dr.
I. Huitinga) in accordance with the formal permissions for brain
autopsy and for the use of human brain material and clinical
information for research purposes.
HISTOLOGY
Brains were dissected at autopsy and the hypothalamus was fixed
in 10% phosphate-buffered formalin at room temperature (RT)
for 1–2 months. After dehydration in graded ethanol series, tis-
sues were cleared in toluene, and embedded in paraffin. Coronal
serial sections (6μm) were cut over the entire rostro-caudal axis
of the hypothalamus. For anatomical orientation, every 100th sec-
tion was collected and mounted on chrome alum-gelatine coated
glass slides and subsequently dried for 2 days at 37◦C, followed by
Nissl staining.
ANTIBODY CHARACTERIZATION
Mouse monoclonal anti-human SERT antibody was purchased
from Millipore, MAb Technologies Inc. (Stone Mountain, GA;
catalog no Mab5618). Antibody specificity has been reported
before and was supported using Western blotting (Bauman et al.,
2000; Ramsey and Defelice, 2002; Serafeim et al., 2002; Henry
et al., 2003). Rabbit polyclonal anti-human AGRP antibody was
obtained from Phoenix Pharmaceuticals (Belmont, CA; catalog
no. H-003-53). AGRP staining disappeared after pre-adsorption
with AGRP and was not affected by cross adsorption using
the NPY peptide (Goldstone et al., 2002). The αMSH antibody
was raised against the αMSH C-terminal, which is modified in
αMSH free acid, and absent in ACTH, minimizing cross reac-
tion with other POMC products. Staining was abolished after
pre-adsorption with the αMSH peptide (Elias et al., 1998).
IMMUNOHISTOCHEMISTRY
Histological and immunocytochemical processing was per-
formed as described previously, with some minor modifica-
tions (Alkemade et al., 2012). For SERT-immunohistochemistry,
a series of coronal sections at 100-section intervals over the
entire rostro-caudal axis of the hypothalamus was mounted on
Superfrost plus slides (Menzel Glaser, Germany) and dried for
at least 2 days at 37◦C. This resulted in 6–12 sections per sub-
ject. Next, antigen retrieval was performed using microwave
treatment (Shi et al., 1997) and sections were stained using
the avidine biotinylated complex method (Hsu et al., 1981),
according to the following protocol: Sections were deparaf-
finised in xylene and rehydrated through graded ethanol series.
After rinsing in distilled water, the sections were washed in
TBS (pH 7.6) and antigen retrieval was performed using
microwave treatment (10min 700W) in TBS (pH 7.6). After
adjustment to RT, sections were incubated in the primary anti-
body diluted 1:5000 in SUMI [supermix, 0.05M Tris, 0.15M
NaCl, 0.5% Triton X-100 (Sigma, Zwijndrecht, The Netherlands),
and 0.25% gelatine (Merck Darmstadt, Germany) (pH 7.6)]
overnight at 4◦C. The slides were rinsed in TBS (pH 7.6,
3 × 5min) and incubated for 1 h at RT in the second anti-
body (biotinylated horse anti-mouse 1:400 in SUMI; Vector
Laboratories, Burlingame, CA). After rinsing in TBS (pH 7.6,
3 × 5min), the sections were incubated 1 h at RT in avi-
dine biotinylated complex (1:800 in SUMI; Vector Laboratories,
Burlingame, CA) and subsequently rinsed in TBS (pH 7.6,
3 × 5min). Finally, sections were incubated in 0.5mg/ml 3,3′-
diaminobenzidine (Sigma) in TBS containing 0.2% ammo-
nium nickel sulphate (BDH; Brunschwig, Amsterdam, The
Netherlands) and 0.01% H2O2 (Merck) for approximately
15min. The reaction was stopped in distilled water. The sec-
tions were dehydrated in ascending series of ethanol, cleared
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Table 1 | Brain material experiment 1.
Subject Sex Age PMD Fix Cause of death, clinical diagnoses
99101 M 69 19 41 Respiratory insufficiency, infarction distal brainstem, alcohol abuse, hypertension
00007 M 85 15 35 Myocardial infarction, bladder carcinoma
03054 M 67 4.5 50 Cardiogenic shock, multi organ failure, type 2 diabetes (insulin, metformin), COPD
98056 F 83 5 41 Respiratory insufficiency, colon carcinoma, type 2 diabetes (no data available on medication), cataract, arthrosis
95016 F 86 13.5 30 Decompensatio cordis, type 2 diabetes (tolbutamide), angina pectoris, nephropathy, retinopathy
01005 F 76 20 36 Respiratory insufficiency, Non-Hodgkin lymphoma, hypertension, basal cell carcinoma
Fix, duration of fixation in days; PMD, post-mortem delay in hours.
Table 2 | Brain material experiment 2.
Subject Sex Age PMD Fix BMI Cause of death, clinical diagnoses
09102 F 92 7 51 15.2 Cachexia, rectal carcinoma, old CVA
98072 M 79 17 31 17.0 Pneumonia, COPD, CVA, renal insufficiency
98091 F 50 41 72 18.8 Respiratory insufficiency, pancoast tumor, metastasized
98027 M 54 8 59 18.9 Bronchopneumonia, sepsis, hepatocellular carcinoma, pneumococcus infection
09075 M 88 7 44 19.6 Respiratory insufficiency, COPD, cardiac insufficiency, PTCA, adenocarcinoma
91205 F 65 9:30 10 20.0 Cardiac failure, mammary carcinoma
10008 M 81 4:50 53 20.3 Angina pectoris, hypercholesterolemia, adenocarcinoma, arthritis
08052 F 62 8 73 21.0 Respiratory insufficiency, renal cell carcinoma, metastasized
98161 F 60 8 87 22.9 Pneumonia, ovarian carcinoma, metastasized
98030 M 63 2:30 108 23.8 Respiratory insufficiency, squamous cell carcinoma of the oropharynx, metastasized
98095 F 75 ND 63 24.0 Respiratory insufficiency, pneumonia, COPD, atrial fibrillation, ischemic heart disease mycosis
fungoides
10039 F 60 7 88 24.2 Cardiac insufficiency, angina pectoris, old CVA
97100 M 76 19 133 25.0 Septic syndrome after aorta bifurcation prosthesis
10013 M 70 6 68 26.0 Pulmonary embolism, adenocarcinoma
08054 F 92 7 67 27.4 Heart failure, melanoma, type 2 diabetes (no data available on medication), cholecystolithiasis,
hepatic steatosis, ileus, cataract
09039 M 82 13 38 27.7 Heart failure, angina pectoris, prostate carcinoma, cataract
01021 M 56 5:30 35 27.8 Myocardial infarction, unsuccessful resuscitation, atrial fibrillation, heart failure
97146 F 100 24 62 30.5 Pneumonia, tibia, and fibula fracture
01005 F 76 19:30 36 32.0 Respiratory insufficiency, Non-hodgkin lymphoma
97065 F 76 14:30 27 32.3 Renal insufficiency, heart failure
09095 F 71 7 53 32.9 Renal insufficiency, hypertensive nephropathy, CVA
97060 M 65 59:30 36 34.7 Myocardial infarction, heart failure, type 2 diabetes (tolbutamide, metformin)
00072 M 78 18 45 39.5 Renal insufficiency, atrial fibrillation, heart failure, dehydration
Fix, duration of fixation in days; PMD, post-mortem delay in hours; BMI, body mass index in kg/m2.
in xylene, and coverslipped using Entellan (Merck, Darmstadt,
Germany).
DOUBLE-LABELING BY IMMUNOHISTOCHEMISTRY
To identify cell types showing basket-like staining of SERT-
immunoreactive fibers in the IFN, we performed immunofluores-
cent double staining of respectively SERT with αMSH (1:20000),
NPY (1:1000), and AGRP (1:3000) in hypothalamic sections
containing the IFN of all 6 subjects.
After overnight primary antibody incubation at 4◦C the slides
were rinsed in TBS (pH 7.6, 3 × 5min) and incubated in the sec-
ondary antibodies (biotinylated horse anti-mouse 1:400 in SUMI;
Vector laboratories, Burlingame, CA) for 1 h at RT. Following
rinsing in TBS (pH 7.6, 3 × 5min), the sections were incubated
1 h at RT in avidine biotinylated complex (1:800 in SUMI; Vector
Laboratories, Burlingame, CA), subsequently rinsed in TBS (pH
7.6, 3 × 5min) and incubated in biotinylated tyramide (1:750 in
SUMI, 0.01% H2O2 (Merck, Darmstadt, Germany)) for 15min
at RT followed by rinsing in TBS (pH 7.6, 3 × 5min). SERT was
detected in green by streptavidin-Alexa488 (1:1000; Invitrogen,
Eugene, Or). The other peptides were visualized in red by respec-
tively anti-rabbit Alexa594 (1:1000; Invitrogen, Eugene, Or) for
NPY or AGRP and anti-sheep Alexa594 (1:1000; Invitrogen,
Eugene, Or) for αMSH. This fluorochrome-conjugated antibody
incubation was performed for 1 h at RT, followed by overnight
incubation at 4◦C.
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Vectashield with DAPI (Vector laboratories, Inc, Burlingame,
CA) was used for nuclear staining and cover slipping. The sections
were stored under dark conditions at 4◦C until further analysis.
Colocalization was assessed by visual inspection.
QUANTITATIVE ANALYSIS
SERT immunoreactivity was quantified using an unbiased
masking procedure of the 3,3′-diaminobenzidine-Ni precipitate
(Alkemade et al., 2012). For quantification of the immunore-
active signal, gray values of the DAB-Ni precipitate in the IFN
were analyzed by computer-assisted densitometry using Image
pro (Media Cybernetics, Silver Spring) and software developed at
the Netherlands Institute for Neuroscience. Every 100th section
containing the IFN was analyzed and estimates of the immunore-
activity weremade by averaging the signal density of the 3 sections
that showed the highest signal, resulting in arbitrary units (a.u.)
(Alkemade et al., 2003).
STATISTICAL ANALYSIS
The data of the second experiment were analyzed with SPSS
for Windows, version 19.0 (SPSS Inc. Chicago, Illinois, USA).
Group differences in numerical variables were evaluated using the
Mann-Whitney U-test for not normally distributed parameters.
A stepwise linear regression analysis was performed to investi-
gate the effects of possible confounding factors. The statistical
significance level for all analyses was set at p < 0.05 (two-sided).
RESULTS
Many SERT-immunoreactive fibers and few scattered SERT-
positive basket cells were found throughout the entire hypotha-
lamus, except in the white matter tracts (Figure 1). Basket-like
staining was defined as aggregation of staining surrounding neu-
ronal cell bodies, creating a basket-like appearance, suggestive
of synaptic innervation. The general distribution of SERT was
comparable in all subjects studied (Figure 1A). A strong inter-
individual variation in staining intensity was observed. SERT
positive fibers were present throughout the entire hypothalamus,
with a denser network of SERT-immunoreactive fibers in the
perifornical area and in close proximity to the anterior commis-
sure. A plexus along the ependyma of the third ventricle wall
also showed strong SERT-immunoreactivity (Figure 1B). In addi-
tion, the highest fiber density was observed in the IFN, and the
suprachiasmatic nucleus, which is the central biological clock
of the human hypothalamus (Figures 1C,D). In these areas, cell
bodies and capillaries were directly surrounded by clusters of
SERT-immunoreactive fibers, highly suggestive of SERT-positive
nerve endings in contact with SERT-negative perikarya and cap-
illaries (high power inserts of Figures 1C,D). The supraoptic
nucleus, paraventricular nucleus, lateral tuberal nucleus, and
tuberomamillary nucleus contained relatively small numbers
of SERT-immunoreactive fibers. No differences were observed
between males and females.
SERT-staining was observed in the IFN of all subjects. IFN
SERT-immunoreactivity was lower in overweight subjects than
in non-overweight subjects (p = 0.036) (Figure 2A). An example
of the difference between overweight and non-overweight sub-
jects is illustrated in Figures 2B,C. A stepwise linear regression
FIGURE 1 | (A) Schematic illustration of the distribution of immunoreactive
serotonin transporter (SERT) fibers in coronal sections (rostral and caudal)
of the human hypothalamus. Abbreviations: AC, anterior commissure; BST,
bed nucleus of the striae terminalis; DBB, diagonal band of Broca; FO,
fornix; IFN, infundibular nucleus; LV, lateral ventricle; NTL, lateral tuberal
nucleus; OT, optic tract; PVN, paraventricular nucleus; SCN, suprachiasmatic
nucleus; SDN, sexually dimorphic nucleus; SON, supraoptic nucleus; TMN,
tuberomamillary nucleus; III, third ventricle. (B) SERT staining, ependymal
layer at the level of the PVN bar = 100μm, (C) suprachiasmatic nucleus,
bar = 250μm, (D) infundibular nucleus, bar = 500μm. ∗Indicates the third
ventricle. High power inserts are from the same anatomical structures.
analysis performed for the factors age, sex, fixation duration, and
post-mortem delay did not reveal any significant results.
To further characterize the cell types showing basket-like stain-
ing of SERT-immunoreactive fibers in the IFN, we performed
immunofluorescent double staining of SERT with NPY, AGRP,
or αMSH on sections containing the IFN. SERT-immunoreactive
fibers were present at all levels in all studied subjects. Many single-
labeled cells expressing NPY, AGRP and αMSH-immunoreactive
cells were found in the IFN in all subjects. A very small minority
of neurons immunoreactive for αMSH or AGRP showed basket-
like SERT staining. As SERT showed no clear colocalization
with NPY, neurons showing basket-like SERT staining remained
largely unidentified (Figures 3, 4). Of note, the labeling of SERT
in the IFN was pre-dominantly localized within the IFN, some-
what lateral to the NPY, AGRP-, and αMSH-immunoreactive
cells. A number of these cells appeared to be strongly activated,
as indicated by the presence of two nucleoli. Together, our results
indicate that SERT axons project to a minority of αMSH and
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FIGURE 2 | (A) SERT immunoreactivity in lean vs. overweight subjects. Illustration of SERT staining in the infundibular nucleus of a lean (B) and an obese (C)
subject.
FIGURE 3 | A series of immunofluorescent photomicrographs showing
serotonin transporter (SERT)- immunostaining (shown in green)
combined with markers for major cell types (shown in red) of
suprachiasmatic nucleus (SCN) and infundibular nucleus (IFN). Cell
nuclei are shown in blue. SERT immunofluorescent staining (green)
combined with (A) arginine vasopressin (AVP, red) in the SCN, high power
insert shows SERT staining in close proximity of AVP-positive neurons
which was observed in a very small minority of cells; (B) Vasointestinal
peptide (VIP, red), high power insert illustrates the absence of SERT
immunoreactivity surrounding VIP-positive neurons; (C) Neuropeptide Y
(NPY, red), and (D) αMelanocyte stimulating hormone (αMSH, red), note
the SERT staining surrounding the αMSH positive neurons.
AGRP neurons, as well as to currently unidentified subgroups of
neurons in the IFN.
DISCUSSION
We showed that SERT protein is extensively expressed in the
human hypothalamus. Moreover, one of the nuclei most heav-
ily innervated was the SCN, which is in agreement with the
FIGURE 4 | Immunofluorescent photomicrographs showing serotonin
transporter (SERT)-immunostaining (shown in green) combined with
immunostaining for Agouti Related Peptide (AGRP) (shown in red). Cell
nuclei are shown in blue. (A) The IFN of subject 00007. Note heavily stained
SERT-positive fibers. The high power insert shows basket-like SERT staining
surrounding neurons which are not immunoreactive for AGRP (B) The IFN
of subject 01005. The high power insert shows an AGRP immunoreactive
cell surrounded by SERT-positive fiber, suggesting nerve ending.
distribution of SERT immunoreactivity reported in rodents
(Legutko and Gannon, 2001) as well as in human and non-
human primates (Moore and Speh, 2004; Emiliano et al., 2007).
Interestingly, when analysing SERT protein in post-mortem sec-
tions of the IFN of overweight and obese subjects and comparing
them to lean individuals, the amount of SERT protein was clearly
reduced in obesity. This is in line with a large number of knockout
and transgenic mouse studies, which, collectively, show an inverse
relationship between brain serotonin signaling and food intake, as
well as with pharmacological studies targeting serotonin signal-
ing in rodents (for review: Lam et al., 2010). We cannot exclude
that BMI in these subjects was influenced by severe illness, includ-
ing malignancies such as adenocarcinomas. In addition, some
subjects received antidiabetic medication. Immunoreactivity for
serotonin has been reported before in the rodent ARC, where
stained fibers were found in the immediate vicinity of capillaries
and neurons (Warembourg and Poulain, 1985). Surprisingly, our
double-labeling study indicates that these SERT immunoreactive
fibers in the IFN only partly belonged to AGRP or αMSH basket
cells. Interestingly, the majority of SERT fibers was located lateral
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to the neuronal populations expressing peptides NPY/AGRP and
αMSH which could point to a role for serotonin in a different
(unidentified) neuronal population. Yet from rodent studies there
are indications of a close relationship between serotonin and NPY
in eating behavior. NPY/AGRP neurons receive serotonin input
(Guy et al., 1988; Heisler and Tecott, 1999), and NPY mRNA is
increased by administration of exogenous serotonin (Choi et al.,
2006). Pharmacological inhibition of serotonin signaling reduced
the feeding effect of NPY administration (Bendotti and Samanin,
1987; Grignaschi et al., 1995; Lam et al., 2010).
Interestingly, another area with dense innervation of SERT
fibers was the suprachiasmatic nucleus (SCN), the area in the
brain were the biological clock resides. This finding on dense
innervation is in agreement with literature showing serotonin as
well as SERT containing fibers in the SCN in other species (for
review: Challet, 2007) and is in line with the important role of
serotonin as regulator of the circadian phase. This innervation
is also likely to affect feeding behavior and glucose metabolism,
which are clearly under the influence of the SCN.
Pharmacological targeting of the serotonin system for the
treatment of obesity has received a lot of attention, but the use
of pharmacological compounds affecting serotonin signaling has
been complicated by unwanted side-effects, such as increased
heart rate, hypertension, headaches, and nausea (Lam and
Heisler, 2007). The use of specific serotonin reuptake inhibitors
for treatment of an array of psychiatric and neurological dis-
orders also shows the importance of serotonin in relation to
body weight. Side-effects of specific serotonin reuptake inhibitors
include increased appetite and increased body weight (Fava, 2000;
Ferguson, 2001; Raeder et al., 2006). Our results on SERT dis-
tribution in the human hypothalamus provides an anatomical
framework for future investigations regarding the role of the sero-
tonergic system in the human hypothalamus in terms of body
weight regulation.
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